Trial Profile
An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Sodium benzoate (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors SyneuRx International (Taiwan) corp
- 10 Sep 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
- 10 Sep 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Sep 2024.
- 06 Apr 2020 Planned End Date changed from 30 Jun 2019 to 31 Dec 2021.